FreshRecalls

⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a very recent recall may be missing. Everything shown is accurate as of the last checked time on this page — for anything time-critical, confirm with the official sources linked below.

FDAClass II · Drug · Recalled June 10, 2026

Amlodipine and Olmesartan Medoxomil Tablets recall — Ascend Laboratories, LLC

Hazard: Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID
D-0556-2026
Brand
Ascend Laboratories
Classification
Class II
Units affected
15,696 x 30's bottles
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Description

Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg, Rx Only, 30-count bottle, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC., Parsippany, NJ 07054, NDC 67877-501-30.

Affected products

Companies & origin

Recalling firm location
Bedminster, NJ, United States
Firm address
135 Us Highway 202 206 Ste 15, 07921-2608

Identifying details (verbatim from the notice)

Product codes / lots
Lot: 24123460, Expires: October 31, 2027.
Distribution
U.S.A. Nationwide
Firm notified the public via
Letter
FDA event ID
98874
Recall initiated
May 5, 2026
FDA classified
June 2, 2026
FDA report date
June 10, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.

Report a data error on this page